Loading…

Indometacin loading and in vitro release properties from novel carbopol coated spherical mesoporous silica nanoparticles

[Display omitted] ► Higher indometacin loading in spherical amino modified MCM-41 nanoparticles. ► Carbopol coating of the amino modified MCM-41 decreased the initial burst release. ► Both the surface modification and the carbopol coating lead to lower cytotoxicity. Spherical MCM-41 silica nanosized...

Full description

Saved in:
Bibliographic Details
Published in:Microporous and mesoporous materials 2013-05, Vol.171, p.131-138
Main Authors: Tzankov, Borislav, Yoncheva, Krassimira, Popova, Margarita, Szegedi, Agnes, Momekov, Georgi, Mihály, Judith, Lambov, Nicolai
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] ► Higher indometacin loading in spherical amino modified MCM-41 nanoparticles. ► Carbopol coating of the amino modified MCM-41 decreased the initial burst release. ► Both the surface modification and the carbopol coating lead to lower cytotoxicity. Spherical MCM-41 silica nanosized particles were synthesized and post synthesis modified by 3-aminopropyltriethoxysilane (APTES) in order to prepare amino-functionalized carrier. Both types of silica particles were loaded with indometacin and further coated with carbopol. The preservation of morphology and pore structure of the particles was observed by XRD, TEM and N2 physisorption. FTIR spectroscopy revealed the interaction between carboxyl groups of indometacin and the amino groups of the functionalized MCM-41. Amino-functionalization of the carrier resulted in higher degree of indometacin loading in comparison to the parent MCM-41, 39% vs. 30%, respectively. The coating of drug loaded amino-MCM-41 silica particles with carbopol significantly reduced the initial burst release of indometacin. Both silica carriers demonstrated no cytotoxicity on HL-60 (acute myeloid leukemia) and K-562 (chronic myeloid leukemia) cell lines.
ISSN:1387-1811
1873-3093
DOI:10.1016/j.micromeso.2012.12.037